Glyco-oncology discussion concluded with success
By Chardelle Prevatt
On Monday, September 19, 2016, GlycoNet scientists joined an elite group of industry experts in Montréal to discuss glycomics and oncology (glyco-oncology).
Featuring Dr. Greg Plowman, VP (oncology research) at Eli Lilly and Company; Dr. Fred Sweeney, VP (business development and strategic alliances) at bioMerieux; and Dr. Luc Marengere, Managing Partner of TVM Capital Life Science, the panel offered invaluable advice to GlycoNet scientists and staff alike. Topics included an overview of glyco-oncology, details on GlycoNet research and challenges and opportunities for translating Network projects into tangible, commercial advances.
“We are truly appreciative of the time given by our industry leaders,” commented GlycoNet Scientific Director Dr. Todd Lowary. “We recognize that our researchers seek to connect and debate relevant topics with their peers and industry colleagues. As such, it is important to facilitate those meetings.”
Dr. Elizabeth Nanak, GlycoNet Executive Director, explained, “The panel discussion not only triggered the exchange of viewpoints, but allowed our scientists to gain firsthand exposure to world-class industry leaders in the field.” She added, “Real-time interaction and feedback of this nature helps to achieve and maintain success.”
Canadian Glycomics Network (GlycoNet) is a pan-Canadian, multidisciplinary research network aiming to deliver solutions to important health issues and improve the quality of life of Canadians through the study of glycomics. GlycoNet is funded by the Networks of Centres of Excellence, a Government of Canada program that supports large-scale, academic-led research networks to build research capacity and accelerate the creation of new knowledge in a specific research area.
For more information:
Canadian Glycomics Network (GlycoNet)
780.492.4355 / firstname.lastname@example.org